Compliance and satisfaction with deferasirox (Exjade®) compared with deferoxamine in patients with transfusion-dependent beta-thalassemia

Hematology

Volumn 19, Issue 4, 2014, Pages 187-191

  Haghpanah, Sezaneh ^a   Zarei, Tahereh ^a   Zahedi, Zohreh ^a   Karimi, Mehran ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Beta thalassemia; Compliance; Convenience; Iron chelation therapy; Satisfaction

Indexed keywords

DEFERASIROX; DEFEROXAMINE; HEMOGLOBIN; BENZOIC ACID DERIVATIVE; IRON CHELATING AGENT; TRIAZOLE DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; BETA THALASSEMIA; BLOOD CELL COUNT; BLOOD TRANSFUSION; CHILD; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; DAILY LIFE ACTIVITY; DRUG CHOICE; DRUG EFFICACY; DRUG USE; ELECTROPHORESIS; FEMALE; HEALTH IMPACT ASSESSMENT; HUMAN; INJECTION SITE IRRITATION; INJECTION SITE PAIN; INTERVIEW; IRAN; LIKERT SCALE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PATIENT SATISFACTION; PRIORITY JOURNAL; SINGLE DRUG DOSE; BETA-THALASSEMIA; INFANT; INJECTION; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PRESCHOOL CHILD; SATISFACTION; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; BENZOATES; BETA-THALASSEMIA; BLOOD TRANSFUSION; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DEFEROXAMINE; FEMALE; HUMANS; INFANT; INJECTIONS; IRON CHELATING AGENTS; MALE; PATIENT COMPLIANCE; PERSONAL SATISFACTION; TRIAZOLES; YOUNG ADULT;

EID: 84901430700     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/1607845413Y.0000000121     Document Type: Article

References (17)

1. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997;89:739-61.
2. Abetz L, Baladi JF, Jones P, Rofail D. The impact of iron overload and its treatment on quality of life: results from a literature review. Health Qual Life Outcomes 2006;4:73.
3. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol. 1996;95:26-36.
4. Alymara V, Bourantas D, Chaidos A, Bouranta P, Gouva M, Vassou A, et al. Effectiveness and safety of combined iron-chela-tion therapy with deferoxamine and deferiprone. Hematol J. 2004;5:475-9.
5. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994;331:567-73.
6. Gabutti V, Borgna-Pignatti C. 9 Clinical manifestations and therapy of transfusional haemosiderosis. Bailliere's Clin Haematol. 1994;7:919-40.
7. Porter J, Huehns E. 11 The toxic effects of desferrioxamine. Bailliere's Clin Haematol. 1989;2:459-74.
8. Vidler V. Compliance with iron chelation therapy in beta thalas-saemia. Paediatr Nurs. 1998;10:17.
9. Duffy-Warren FCA, Rigourd S, Frederick A. Exjade (defera-sirox) Basic Prescribing Information. 2008.
10. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with ß-thalassemia. Blood 2006;107:3455-62.
11. Rofail D, Abetz L, Viala M, Gait C, Baladi JF, Payne K. Satisfaction and adherence in patients with iron overload receiving iron chelation therapy as assessed by a newly developed patient instrument. Value Health 2009;12:109-17.
12. Cappellini MD, Bejaoui M, Agaoglu L, Porter J, Coates T, Jeng M, et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with ß-thalassemia. Clin Ther. 2007;29:909-17.
13. Taher A, Al Jefri A, Elalfy M, Al Zir K, Daar S, Rofail D, et al. Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with ß-thalassemia: results from the ESCALATOR trial. Acta Haematol. 2010; 123:220-5.
14. Vichinsky E, Pakbaz Z, Onyekwere O, Porter J, Swerdlow P, Coates T, et al. Patient-reported outcomes of deferasirox (Exjade®, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Acta Haematol. 2008;119:133-41.
15. Taher A, El-Beshlawy A, Elalfy MS, Al Zir K, Daar S, Habr D, et al. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with ß-thalassaemia: the ESCALATOR study. Eur J Haematol. 2009;82:458-65.
16. Taher A, Cappellini MD. Update on the use of deferasirox in the management of iron overload. Ther Clin Risk Manag. 2009;5:857.
17. Vichinsky E, Onyekwere O, Porter J, Swerdlow P, Eckman J, Lane P, et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2006;136:501-8.